Affinity Asset Advisors LLC Buys Shares of 559,163 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Affinity Asset Advisors LLC acquired a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 559,163 shares of the company's stock, valued at approximately $1,197,000. Affinity Asset Advisors LLC owned approximately 0.99% of Black Diamond Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDTX. Bank of New York Mellon Corp raised its position in shares of Black Diamond Therapeutics by 46.1% during the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company's stock valued at $443,000 after buying an additional 65,341 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Black Diamond Therapeutics by 7.9% in the fourth quarter. Wellington Management Group LLP now owns 221,236 shares of the company's stock valued at $473,000 after purchasing an additional 16,279 shares in the last quarter. Sei Investments Co. bought a new stake in Black Diamond Therapeutics in the fourth quarter worth $49,000. FMR LLC bought a new stake in shares of Black Diamond Therapeutics in the 3rd quarter valued at approximately $779,000. Finally, Barclays PLC boosted its holdings in shares of Black Diamond Therapeutics by 201.9% in the 3rd quarter. Barclays PLC now owns 78,151 shares of the company's stock worth $339,000 after purchasing an additional 52,265 shares during the period. Institutional investors own 95.47% of the company's stock.

Black Diamond Therapeutics Stock Up 5.9 %

Shares of NASDAQ:BDTX traded up $0.08 during trading on Friday, hitting $1.44. 662,839 shares of the stock traded hands, compared to its average volume of 1,482,117. The company has a market cap of $81.59 million, a price-to-earnings ratio of -1.08 and a beta of 2.81. The company has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $2.34. Black Diamond Therapeutics, Inc. has a 52-week low of $1.20 and a 52-week high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. On average, equities research analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Insider Activity

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares of the company's stock, valued at $5,658,442.29. The trade was a 67.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 8.87% of the company's stock.

Wall Street Analyst Weigh In

BDTX has been the subject of several recent analyst reports. Stifel Nicolaus dropped their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright raised their price objective on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, March 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $14.60.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.